Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...

USA: A study published in Obesity Pillars has revealed that individuals taking GLP-1 receptor agonists (GLP-1RAs) experienced ...

Midlife weight gain is a persistent challenge for many women, but emerging research suggests hormone therapy may enhance response to glucagon-like peptide-1 (GLP-1)–based treatments.

In patients with type 2 diabetes (T2D), the risk of major adverse cardiovascular events (MACEs) was lowest among patients ...

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Analysts have set 12-month price targets for West Pharmaceutical Servs, revealing an average target of $336.2, a high ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

CHICAGO -- A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST ...

The EMA is working with social media content creators to try to encourage "safe and responsible" use of weight-loss drugs.

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and ...